Clinical Trials Logo

Relapsed Pediatric AML clinical trials

View clinical trials related to Relapsed Pediatric AML.

Filter by:
  • None
  • Page 1

NCT ID: NCT05622591 Withdrawn - Clinical trials for Acute Myeloid Leukemia

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML

Pediatric AML
Start date: March 2024
Phase: Phase 1
Study type: Interventional

This research study was planned to focus on a rare type of acute myeloid leukemia (with the subtype CBFA2T3::GLIS2 that overexpresses folate receptor alpha (FRα) (a protein on the surface of leukemia cells)) that has relapsed or is refractory. Relapse means the cancer has come back after treatment. Refractory means the cancer does not respond to treatment.

NCT ID: NCT04562792 Completed - Clinical trials for Refractory Acute Myeloid Leukemia

Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia

Start date: May 8, 2020
Phase: Phase 2
Study type: Interventional

In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days. Once the patient has received 5 doses of daunorubicin, subsequent therapy will be at the discretion of the primary oncology team.

NCT ID: NCT04033627 Recruiting - Clinical trials for Relapsed Pediatric ALL

TCDαβ/CD45RA Haploidentical Transplantation in Children With Leukemia

Start date: November 10, 2020
Phase: N/A
Study type: Interventional

This is a multi-center clinical study in China using CliniMACS TCRα/β+ and CD45RA+ T cell depleted stem cell grafts from haploidentical donors for hematopoietic stem cell transplantation in children.

NCT ID: NCT03245424 Approved for marketing - Clinical trials for Acute Myeloid Leukemia

Ivosidenib Expanded Access Program in Relapsed/Refractory AML With an IDH1 Mutation

Start date: n/a
Phase:
Study type: Expanded Access

To provide access to ivosidenib monotherapy to patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation.

NCT ID: NCT02638428 Recruiting - Clinical trials for Relapsed Pediatric AML

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Start date: December 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and feasibility of combination chemotherapy with target agents according to the result of targeted deep sequencing in pediatric patients with relapsed/refractory solid tumor or AML.